SASP: Tumor Suppressor or Promoter? Yes!

Trends in Cancer

Volumn 2, Issue 11, 2016, Pages 676-687

  Rao, Sonia G ^a   Jackson, James G ^a  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

chemotherapy response; immune response; p53; SASP; senescence; tumor suppression

Indexed keywords

CANCER CELL; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER RECURRENCE; CARCINOGENESIS; HUMAN; PHENOTYPE; PRIORITY JOURNAL; REVIEW; SENESCENCE; SENESCENCE ASSOCIATED SECRETORY PHENOTYPE; TREATMENT RESPONSE; ANIMAL; CELL AGING; CELL TRANSFORMATION; NEOPLASM; PATHOLOGY; TUMOR RECURRENCE;

ANIMALS; CARCINOGENESIS; CELL TRANSFORMATION, NEOPLASTIC; CELLULAR SENESCENCE; HUMANS; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS; PHENOTYPE;

EID: 85001075425     PISSN: 24058033     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trecan.2016.10.001     Document Type: Review

References (108)

1. 1 Perez-Mancera, P.A., et al. Inside and out: the activities of senescence in cancer. Nat. Rev. Cancer 14 (2014), 547–558.
2. 2 Hayflick, L., The limited in vitro lifetime of human diploid cell strains. Exp. Cell Res. 37 (1965), 614–636.
3. 3 Lowe, S.W., et al. Intrinsic tumour suppression. Nature 432 (2004), 307–315.
4. 4 Campisi, J., Cellular senescence as a tumor-suppressor mechanism. Trends Cell Biol. 11 (2001), S27–S31.
5. 5 Tonnessen-Murray, C., et al. The regulation of cellular functions by the p53 protein: cellular senescence. Lozano, G., Levine, A.J., (eds.) The p53 Protein: From Cell Regulation to Cancer, 2016, Cold Spring Harbor Laboratory Press, 173–186.
6. 6 Kuilman, T., et al. The essence of senescence. Genes. Dev. 24 (2010), 2463–2479.
7. 7 Campisi, J., Senescent cells, tumor suppression, and organismal aging: good citizens, bad neighbors. Cell 120 (2005), 513–522.
8. 8 Hornsby, P.J., Cellular senescence and tissue aging in vivo. J. Gerontol. A. Biol. Sci. Med. Sci. 57 (2002), B251–B256.
9. 9 Baker, D.J., et al. Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders. Nature 479 (2011), 232–236.
10. 10 Baker, D.J., et al. Naturally occurring p16(Ink4a)-positive cells shorten healthy lifespan. Nature 530 (2016), 184–189.
11. 11 Collado, M., Serrano, M., Senescence in tumours: evidence from mice and humans. Nat. Rev. Cancer 10 (2010), 51–57.
12. 12 Sharpless, N.E., Sherr, C.J., Forging a signature of in vivo senescence. Nat. Rev. Cancer 15 (2015), 397–408.
13. 13 Chang, B.D., et al. A senescence-like phenotype distinguishes tumor cells that undergo terminal proliferation arrest after exposure to anticancer agents. Cancer Res. 59 (1999), 3761–3767.
14. 14 Shay, J.W., Roninson, I.B., Hallmarks of senescence in carcinogenesis and cancer therapy. Oncogene 23 (2004), 2919–2933.
15. 15 Malaquin, N., et al. Keeping the senescence secretome under control: molecular reins on the senescence-associated secretory phenotype. Exp. Gerontol. 82 (2016), 39–49.
16. 16 Rodier, F., et al. Persistent DNA damage signalling triggers senescence-associated inflammatory cytokine secretion. Nat. Cell Biol. 11 (2009), 973–979.
17. 17 Coppe, J.P., et al. Tumor suppressor and aging biomarker p16(INK4a) induces cellular senescence without the associated inflammatory secretory phenotype. J. Biol. Chem. 286 (2011), 36396–36403.
18. 18 Coppe, J.P., et al. Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLoS Biol. 6 (2008), 2853–2868.
19. 19 Vallabhapurapu, S., Karin, M., Regulation and function of NF-kappaB transcription factors in the immune system. Annu. Rev. Immunol. 27 (2009), 693–733.
20. 20 Acosta, J.C., et al. Chemokine signaling via the CXCR2 receptor reinforces senescence. Cell 133 (2008), 1006–1618.
21. 21 Chien, Y., et al. Control of the senescence-associated secretory phenotype by NF-kappaB promotes senescence and enhances chemosensitivity. Genes Dev. 25 (2011), 2125–2136.
22. 22 Hardy, K., et al. Transcriptional networks and cellular senescence in human mammary fibroblasts. Mol. Biol. Cell 16 (2005), 943–953.
23. 23 Ohanna, M., et al. Senescent cells develop a PARP-1 and nuclear factor-{kappa}B-associated secretome (PNAS). Genes Dev. 25 (2011), 1245–1261.
24. 24 Wang, J., et al. RelA/p65 functions to maintain cellular senescence by regulating genomic stability and DNA repair. EMBO Rep. 10 (2009), 1272–1278.
25. 25 Rovillain, E., et al. Activation of nuclear factor-kappa B signalling promotes cellular senescence. Oncogene 30 (2011), 2356–2366.
26. 26 Freund, A., et al. p38MAPK is a novel DNA damage response-independent regulator of the senescence-associated secretory phenotype. EMBO J. 30 (2011), 1536–1548.
27. 27 Janssens, S., Tschopp, J., Signals from within: the DNA-damage-induced NF-kappaB response. Cell Death Differ. 13 (2006), 773–784.
28. 28 Olivieri, F., et al. DNA damage response (DDR) and senescence: shuttled inflamma-miRNAs on the stage of inflamm-aging. Oncotarget 6 (2015), 35509–35521.
29. 29 Alexander, E., et al. IkappaBzeta is a regulator of the senescence-associated secretory phenotype in DNA damage- and oncogene-induced senescence. J. Cell Sci. 126 (2013), 3738–3745.
30. 30 Ohanna, M., et al. Secretome from senescent melanoma engages the STAT3 pathway to favor reprogramming of naive melanoma towards a tumor-initiating cell phenotype. Oncotarget 4 (2013), 2212–2224.
31. 31 Jackson, J.G., et al. p53-mediated senescence impairs the apoptotic response to chemotherapy and clinical outcome in breast cancer. Cancer Cell 21 (2012), 793–806.
32. 32 Canino, C., et al. SASP mediates chemoresistance and tumor-initiating-activity of mesothelioma cells. Oncogene 31 (2012), 3148–3163.
33. 33 Kang, C., et al. The DNA damage response induces inflammation and senescence by inhibiting autophagy of GATA4. Science, 349, 2015, aaa5612.
34. 34 te Poele, R.H., et al. DNA damage is able to induce senescence in tumor cells in vitro and in vivo. Cancer Res. 62 (2002), 1876–1883.
35. 35 Jackson, J.G., Pereira-Smith, O.M., Primary and compensatory roles for RB family members at cell cycle gene promoters that are deacetylated and downregulated in doxorubicin-induced senescence of breast cancer cells. Mol. Cell Biol. 26 (2006), 2501–2510.
36. 36 Symmans, W.F., et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J. Clin. Oncol. 25 (2007), 4414–4422.
37. 37 Bertheau, P., et al. TP53 status and response to chemotherapy in breast cancer. Pathobiology 75 (2008), 132–139.
38. 38 Murphy, K., et al. Janeway's Immunobiology. 2012, Garland Science.
39. 39 Pyzer, A.R., et al. Myeloid-derived suppressor cells as effectors of immune suppression in cancer. Int. J. Cancer 39 (2016), 1915–1926.
40. 40 Kuilman, T., et al. Oncogene-induced senescence relayed by an interleukin-dependent inflammatory network. Cell 133 (2008), 1019–1031.
41. 41 Wajapeyee, N., et al. Oncogenic BRAF induces senescence and apoptosis through pathways mediated by the secreted protein IGFBP7. Cell, 132, 2008 363-274.
42. 42 Guo, H., et al. Chemokine receptor CXCR2 is transactivated by p53 and induces p38-mediated cellular senescence in response to DNA damage. Aging Cell 12 (2013), 1110–1121.
43. 43 Acosta, J.C., et al. A complex secretory program orchestrated by the inflammasome controls paracrine senescence. Nat. Cell Biol. 15 (2013), 978–990.
44. 44 Kang, T.W., et al. Senescence surveillance of pre-malignant hepatocytes limits liver cancer development. Nature 479 (2011), 547–551.
45. 45 Tasdemir, N., et al. BRD4 connects enhancer remodeling to senescence immune surveillance. Cancer Discov. 6 (2016), 612–629.
46. 46 Iannello, A., et al. p53-dependent chemokine production by senescent tumor cells supports NKG2D-dependent tumor elimination by natural killer cells. J. Exp. Med. 210 (2013), 2057–2069.
47. 47 Xue, W., et al. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 445 (2007), 656–660.
48. 48 Krizhanovsky, V., et al. Senescence of activated stellate cells limits liver fibrosis. Cell 134 (2008), 657–667.
49. 49 Lujambio, A., et al. Non-cell-autonomous tumor suppression by p53. Cell 153 (2013), 449–460.
50. 50 Kansara, M., et al. Immune response to RB1-regulated senescence limits radiation-induced osteosarcoma formation. J. Clin. Invest. 123 (2013), 5351–5360.
51. 51 Lesina, M., et al. RelA regulates CXCL1/CXCR2-dependent oncogene-induced senescence in murine Kras-driven pancreatic carcinogenesis. J. Clin. Invest. 126 (2016), 2919–2932.
52. 52 Pribluda, A., et al. A senescence-inflammatory switch from cancer-inhibitory to cancer-promoting mechanism. Cancer Cell 24 (2013), 242–256.
53. 53 Marmary, Y., et al. Radiation-induced loss of salivary gland function is driven by cellular senescence and prevented by IL6 modulation. Cancer Res. 76 (2016), 1170–1180.
54. 54 Krtolica, A., et al. Senescent fibroblasts promote epithelial cell growth and tumorigenesis: a link between cancer and aging. Proc. Natl. Acad. Sci. U.S.A. 98 (2001), 12072–12077.
55. 55 Parrinello, S., et al. Stromal-epithelial interactions in aging and cancer: senescent fibroblasts alter epithelial cell differentiation. J. Cell Sci. 118 (2005), 485–496.
56. 56 Liu, D., Hornsby, P.J., Senescent human fibroblasts increase the early growth of xenograft tumors via matrix metalloproteinase secretion. Cancer Res. 67 (2007), 3117–3126.
57. 57 Gosselin, K., et al. Senescence-associated oxidative DNA damage promotes the generation of neoplastic cells. Cancer Res. 69 (2009), 7917–7925.
58. 58 Malaquin, N., et al. Senescent fibroblasts enhance early skin carcinogenic events via a paracrine MMP-PAR-1 axis. PLoS ONE, 8, 2013, e63607.
59. 59 Bhatia, B., et al. Evidence that senescent human prostate epithelial cells enhance tumorigenicity: cell fusion as a potential mechanism and inhibition by p16INK4a and hTERT. Int. J. Cancer 122 (2008), 1483–1495.
60. 60 Angelini, P.D., et al. Constitutive HER2 signaling promotes breast cancer metastasis through cellular senescence. Cancer Res. 73 (2013), 450–458.
61. 61 Zacarias-Fluck, M.F., et al. Effect of cellular senescence on the growth of HER2–positive breast cancers. J. Natl. Cancer Inst., 107, 2015, djv020.
62. 62 Di, G.H., et al. IL-6 secreted from senescent mesenchymal stem cells promotes proliferation and migration of breast cancer cells. PLoS ONE, 9, 2014, e113572.
63. 63 Chen, Z., et al. Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature 436 (2005), 725–730.
64. 64 Alimonti, A. et al. A novel type of cellular senescence that can be enhanced in mouse models and human tumor xenografts to suppress prostate tumorigenesis. J Clin Invest 120, 681–693.
65. 65 Toso, A., et al. Enhancing chemotherapy efficacy in Pten-deficient prostate tumors by activating the senescence-associated antitumor immunity. Cell Rep. 9 (2014), 75–89.
66. 66 Di Mitri, D., et al. Tumour-infiltrating Gr-1 + myeloid cells antagonize senescence in cancer. Nature 515 (2014), 134–137.
67. 67 Hoare, M., et al. NOTCH1 mediates a switch between two distinct secretomes during senescence. Nat. Cell Biol. 18 (2016), 979–992.
68. 68 Ruhland, M.K., et al. Stromal senescence establishes an immunosuppressive microenvironment that drives tumorigenesis. Nat. Commun., 7, 2016, 11762.
69. 69 Capell, B.C., et al. MLL1 is essential for the senescence-associated secretory phenotype. Genes Dev. 30 (2016), 321–336.
70. 70 Orjalo, A.V., et al. Cell surface-bound IL-1 alpha is an upstream regulator of the senescence-associated IL-6/IL-8 cytokine network. Proc. Natl. Acad. Sci. U.S.A. 106 (2009), 17031–17036.
71. 71 Laberge, R.M., et al. MTOR regulates the pro-tumorigenic senescence-associated secretory phenotype by promoting IL1A translation. Nat. Cell Biol. 17 (2015), 1049–1061.
72. 72 Herranz, N., et al. mTOR regulates MAPKAPK2 translation to control the senescence-associated secretory phenotype. Nat. Cell Biol. 17 (2015), 1205–1217.
73. 73 Xu, M., et al. JAK inhibition alleviates the cellular senescence-associated secretory phenotype and frailty in old age. Proc. Natl. Acad. Sci. U.S.A. 112 (2015), E6301–E6310.
74. 74 Yosef, R., et al. Directed elimination of senescent cells by inhibition of BCL-W and BCL-XL. Nat. Commun., 7, 2016, 11190.
75. 75 Cory, S. et al. Targeting BCL-2-like proteins to kill cancer cells. Trends in Cancer 2, 443–460.
76. 76 Chang, J., et al. Clearance of senescent cells by ABT263 rejuvenates aged hematopoietic stem cells in mice. Nat. Med. 22 (2016), 78–83.
77. 77 Zhu, Y., et al. Identification of a novel senolytic agent, navitoclax, targeting the Bcl-2 family of anti-apoptotic factors. Aging Cell 15 (2016), 428–435.
78. 78 Zhu, Y., et al. The Achilles’ heel of senescent cells: from transcriptome to senolytic drugs. Aging Cell 14 (2015), 644–658.
79. 79 Acharyya, S., et al. A CXCL1 paracrine network links cancer chemoresistance and metastasis. Cell 150 (2012), 165–178.
80. 80 Novakova, Z., et al. Cytokine expression and signaling in drug-induced cellular senescence. Oncogene 29 (2010), 273–284.
81. 81 Cahu, J., et al. Senescence-associated secretory phenotype favors the emergence of cancer stem-like cells. Cell Death Dis., 3, 2012, e446.
82. 82 Vilgelm, A.E., et al. Connecting the dots: therapy-induced senescence and a tumor-suppressive immune microenvironment. J. Natl. Cancer Inst., 108, 2016, djv406.
83. 83 Liu, Y., et al. Targeting aurora kinases limits tumour growth through DNA damage-mediated senescence and blockade of NF-kappaB impairs this drug-induced senescence. EMBO Mol. Med. 5 (2013), 149–166.
84. 84 Bertheau, P., et al. Effect of mutated TP53 on response of advanced breast cancers to high-dose chemotherapy. Lancet 360 (2002), 852–854.
85. 85 Bertheau, P., et al. Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin-cyclophosphamide regimen. PLoS Med., 4, 2007, e90.
86. 86 Chen, M.B., et al. Value of TP53 status for predicting response to neoadjuvant chemotherapy in breast cancer: a meta-analysis. PLoS ONE, 7, 2012, e39655.
87. 87 Esserman, L.J., et al. Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). Br. Cancer Res. Treat. 132 (2012), 1049–1062.
88. 88 Wang, Y., et al. TP53 mutations are associated with higher rates of pathologic complete response to anthracycline/cyclophosphamide-based neoadjuvant chemotherapy in operable primary breast cancer. Int. J. Cancer 138 (2015), 489–496.
89. 89 Wong, K.K., et al. Poor survival with wild-type TP53 ovarian cancer?. Gynecol. Oncol. 130 (2013), 565–569.
90. 90 Moreno, C.S., et al. Evidence that p53-mediated cell-cycle-arrest inhibits chemotherapeutic treatment of ovarian carcinomas. PLoS ONE, 2, 2007, e441.
91. 91 Roberson, R.S., et al. Escape from therapy-induced accelerated cellular senescence in p53-null lung cancer cells and in human lung cancers. Cancer Res. 65 (2005), 2795–2803.
92. 92 Sidi, R., et al. Induction of senescence markers after neo-adjuvant chemotherapy of malignant pleural mesothelioma and association with clinical outcome: an exploratory analysis. Eur. J. Cancer 47 (2011), 326–332.
93. 93 Wu, P.C., et al. Accelerated cellular senescence in solid tumor therapy. Exp. Oncol. 34 (2012), 298–305.
94. 94 Bataille, F., et al. Alterations in p53 predict response to preoperative high dose chemotherapy in patients with gastric cancer. Mol. Pathol. 56 (2003), 286–292.
95. 95 Choi, W., et al. Identification of distinct Basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell 25 (2014), 152–165.
96. 96 Rau, B., et al. Dynamic expression profile of p21WAF1/CIP1 and Ki-67 predicts survival in rectal carcinoma treated with preoperative radiochemotherapy. J. Clin. Oncol. 21 (2003), 3391–3401.
97. 97 Tato-Costa, J., et al. Therapy-induced cellular senescence induces epithelial-to-mesenchymal transition and increases invasiveness in rectal cancer. Clin. Colorectal Cancer 15 (2016), 170–178.
98. 98 Ma, C.X., et al. Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models. J. Clin. Invest. 122 (2012), 1541–1552.
99. 99 Takamori, H., et al. Autocrine growth effect of IL-8 and GROalpha on a human pancreatic cancer cell line, Capan-1. Pancreas 21 (2000), 52–56.
100. 100 Dhawan, P., Richmond, A., Role of CXCL1 in tumorigenesis of melanoma. J. Leukoc. Biol. 72 (2002), 9–18.
101. 101 Yang, X., et al. Essential contribution of a chemokine, CCL3, and its receptor, CCR1, to hepatocellular carcinoma progression. Int. J. Cancer 118 (2006), 1869–1876.
102. 102 Begley, L.A., et al. CXCL5 promotes prostate cancer progression. Neoplasia 10 (2008), 244–254.
103. 103 Karnoub, A.E., Weinberg, R.A., Chemokine networks and breast cancer metastasis. Breast Dis. 26 (2006), 75–85.
104. 104 Coppe, J.P., et al. Secretion of vascular endothelial growth factor by primary human fibroblasts at senescence. J. Biol. Chem. 281 (2006), 29568–29574.
105. 105 Achuthan, S., et al. Drug-induced senescence generates chemoresistant stemlike cells with low reactive oxygen species. J. Biol. Chem. 286 (2011), 37813–37829.
106. 106 Basu, D., et al. Role of the beta catenin destruction complex in mediating chemotherapy-induced senescence-associated secretory phenotype. PLoS ONE, 7, 2012, e52188.
107. 107 Jeon, H.Y., et al. Irradiation induces glioblastoma cell senescence and senescence-associated secretory phenotype. Tumour Biol. 37 (2016), 5857–5867.
108. 108 Gilbert, L.A., Hemann, M.T., DNA damage-mediated induction of a chemoresistant niche. Cell 143 (2010), 355–366.